339P Analysis of first- and second-line immunotherapy efficacy in metastatic non-small cell lung cancer with low PD-L1 expression

C Mckay,J Cheng,P.Y Yip,A Tognela,V.J Bray,P.S Kok

doi:10.1016/j.annonc.2022.10.377

339P Analysis of first- and second-line immunotherapy efficacy in metastatic non-small cell lung cancer with low PD-L1 expression

C Mckay, J Cheng + Show 4 more

Open Access

https://doi.org/10.1016/j.annonc.2022.10.377

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Nov 1, 2022
License type: publisher-specific-oa

Affiliation: Western Sydney University

#Second-line Immune Checkpoint Inhibitors #Outcomes Of Advanced Non-small Cell Lung Cancer Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Immune checkpoint inhibitors (ICI) improve overall survival (OS) in non-small cell lung cancer (NSCLC) but the efficacy of first- vs second-line ICI is unknown. We compared the outcomes of advanced NSCLC patients with <50% PD-L1 expression who received first- and second-line ICI.

Full Text